Enables retinoic acid binding activity. Involved in retinoic acid biosynthetic process. Located in cytosol. Orthologous to human CRABP2 (cellular retinoic acid binding protein 2); PARTICIPATES IN retinoic acid metabolic pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4-tert-Octylphenol; 9-cis-retinoic acid.
[Tretinoin co-treated with alpha-Tocopherol] results in increased expression of CRABP2 mRNA, [Tretinoin co-treated with alpha-Tocopherol] results in increased expression of CRABP2 protein
[Estradiol co-treated with TGFB1 protein] results in decreased expression of CRABP2 mRNA, [Progesterone co-treated with Estradiol] results in decreased expression of CRABP2 mRNA
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CRABP2 mRNA, Tetrachlorodibenzodioxin inhibits the reaction [Tretinoin results in increased expression of CRABP2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[Disulfiram binds to Copper] which results in decreased expression of CRABP2 mRNA, [NSC 689534 binds to Copper] which results in decreased expression of CRABP2 mRNA
[Disulfiram binds to Copper] which results in decreased expression of CRABP2 mRNA, [NSC 689534 binds to Copper] which results in decreased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA